Digoxin is a selective modifier increasing platinum drug anticancer activity
| Autor: | Z. S. Shprakh, E. A. Bogush, Sergei Tjulandin, B.E. Polotsky, Mikhail Davydov, V. Yu. Chernov, T. A. Bogush, E. A. Dudko |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Drug Digoxin medicine.medical_treatment media_common.quotation_subject Intraperitoneal injection Biophysics Antineoplastic Agents Breast Neoplasms Pharmacology Biochemistry 03 medical and health sciences 0302 clinical medicine Breast cancer Ascites medicine Animals Glycolysis Carcinoma Ehrlich Tumor Cardiac glycoside media_common Cisplatin Dose-Response Relationship Drug business.industry General Chemistry General Medicine medicine.disease 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Mice Inbred CBA Drug Therapy Combination Female medicine.symptom business Neoplasm Transplantation medicine.drug |
| Zdroj: | Doklady. Biochemistry and biophysics. 468(1) |
| ISSN: | 1608-3091 |
| Popis: | Using the model of breast cancer Ehrlich ascites tumor in mice, we showed that a sigle intraperitoneal injection of cardiac glycoside digoxin 1 h before the intraperitoneal injection of cisplatin increased the anticancer effect of the cytostatic drug more than twice when recalculated for the dose. It is assumed that the modifying effect of digoxin is determined by the direct inhibition of glycolysis in tumor cells. Taking into account the design of the study, we consider promising the clinical evaluation of the effectiveness of digoxin as a modifier of cisplatin efficiency in intracavitary therapy of ascites cancers with pleural and abdominal dissenmination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|